This expert group aims to discuss innovative proposals to stimulate innovation and foster research into new orphan drugs and therapies for rare diseases.
In the driving seat of the project there are EURORDIS, the non-governmental rare diseases patient-driven alliance, and EUCOPE, the European association for small to medium-sized companies in the field of pharmaceuticals and medical technologies, many of which focused on rare diseases. The group was established in the light of the upcoming Pharmaceutical Strategy and ongoing Evaluation of the Orphan Medicinal Products (OMP) Regulation.
Six companies from EUCOPE provide expertise and financial resources to support this initiative: Alexion, Biogen, Bristol Myers Squibb, Chiesi, PTC Therapeutics and Takeda.
The co-chairs of the group are former MEP Renate Sommer, and Professor Maurizio Scarpa, coordinator of MetaBERN and Chairman of the European Reference Networks Board of Coordinators (ERN-BC).
The Expert Group is focusing on three areas to develop concrete policy proposals for potential improvements of the European OMP Incentives environment. These areas are:1. Prioritisation and optimisation
The European Expert Group on Orphan Drug Incentives will aim to publish concrete proposals on how to improve the OMP regulation by early 2021.
For further information, visit the OD Expert Group’s website: www.OD-ExpertGroup.eu